MARKET

STML

STML

Stemline
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.760
+0.030
+0.63%
After Hours: 4.760 0 0.00% 16:00 04/08 EDT
OPEN
4.780
PREV CLOSE
4.730
HIGH
4.950
LOW
4.710
VOLUME
601.30K
TURNOVER
--
52 WEEK HIGH
18.22
52 WEEK LOW
3.210
MARKET CAP
239.79M
P/E (TTM)
-2.5493
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average STML stock price target is 17.64 with a high estimate of 41.00 and a low estimate of 9.00.

EPS

STML News

More
  • Edited Transcript of STML earnings conference call or presentation 16-Mar-20 12:00pm GMT
  • Thomson Reuters StreetEvents · 03/30 17:03
  • Stemline Therapeutics (STML) Investor Presentation - Slideshow
  • Seeking Alpha - Article · 03/17 21:21
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Wedbush Maintains Outperform on Stemline Therapeutics, Lowers Price Target to $11
  • Benzinga · 03/17 15:32

Industry

Biotechnology & Medical Research
+3.08%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About STML

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
More

Webull offers kinds of Stemline Therapeutics Inc stock information, including NASDAQ:STML real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, STML stock news, and many more online research tools to help you make informed decisions.